Colinz Laboratories reported an audited net profit of ₹240.12 lakh for the quarter ended June 30, 2026, a 1,913.6% increase from ₹11.92 lakh in the same period last year. The Board approved these audited financial results on July 30, 2026, marking a significant upgrade from the previously unaudited figures. The substantial profit jump was primarily driven by non-operating gains, specifically the receipt of the second and final tranche of proceeds from the sale of its factory land, building, and machinery at Sinnar, Maharashtra. Despite the headline profit surge, revenue from operations fell to ₹136.26 lakh from ₹164.13 lakh in Q1FY26, indicating continued pressure on core business activities.

The Independent Auditors have issued an unqualified audit opinion on the Q1FY27 results, providing greater assurance on the financial statements compared to the earlier limited review. The company’s total comprehensive income rose to ₹253.78 lakh from ₹21.05 lakh in the prior year quarter. While manufacturing activities at the sold facility continue on a loan license or third-party basis, the disposal of assets has significantly altered the company’s balance sheet structure and cash inflows for the period. The Board also approved the Director’s Report, Management Discussion Report, and Corporate Governance Report for the fiscal year ended March 31, 2026, during the same meeting.

Key Financial Metrics

What the Numbers Show

The divergence between operational performance and net profit highlights the impact of one-time events on Colinz Laboratories’ financials. Revenue from operations declined by 17.0%, dropping to ₹136.26 lakh from ₹164.13 lakh in Q1FY26. This decline suggests ongoing challenges in the pharmaceutical formulation segment. However, the net profit before tax surged to ₹290.12 lakh from ₹16.07 lakh, largely due to the exceptional gain from the Sinnar asset sale. Without this non-operating income, the underlying profitability would have remained subdued, similar to the previous year’s levels. The unqualified audit opinion confirms that these transactions were accounted for correctly, but investors should note that the profit growth is not sustainable through core operations alone.

Governance and Administrative Updates

The Board appointed Mrs. Vijaya Mani (DIN 11363910) as Director (Promoter & Non-Executive), liable to retire by rotation, effective from the forthcoming Annual General Meeting. Additionally, Mr. N. K. Menon (DIN 01111297) was recommended for appointment as Whole Time Director and CEO for a term of one year, from October 1, 2026, to September 30, 2027. The company has scheduled its 40th AGM for September 22, 2026, with the Register of Members closed from September 15, 2026, to September 22, 2026. Electronic voting will be open from September 19, 2026, to September 21, 2026, with a cut-off date of September 15, 2026, for determining eligible shareholders.

A group of acquirers comprising Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Padam Dugar as the Person Acting in Concert (PAC), has announced a mandatory open offer to acquire up to 6,54,966 fully paid-up equity shares of Colinz Laboratories Limited . The offer represents 26% of the voting share capital of the company and is priced at ₹54 per share, aggregating to a total consideration of ₹3.53 crore.

The open offer follows the execution of a Share Purchase Agreement (SPA) dated June 18, 2026, between the acquirers and Vijaya Mani, the existing promoter and selling shareholder. Under the SPA, the acquirers agreed to purchase 8,70,500 equity shares, constituting 34.56% of the voting share capital, at a price of ₹50 per share. Upon completion of this transaction, the acquirers' shareholding will increase to 37.01%, triggering the mandatory open offer in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Offer Details

The offer price of ₹54 per share has been determined in accordance with SEBI regulations, considering the highest negotiated price under the SPA and the volume-weighted average market price. The acquirers have stated that they do not intend to delist the equity shares of the company. The offer is not conditional upon a minimum level of acceptance and is not a competitive offer.

Financial Arrangements

To fund the offer, the acquirers have opened an escrow cash account with ICICI Bank and deposited ₹89 lakh, which is more than 25% of the total offer consideration. Saffron Capital Advisors Private Limited has been appointed as the Manager to the Open Offer, while Bigshare Services Private Limited acts as the Registrar.

Tentative Schedule

The tendering period for the open offer is scheduled to commence on August 11, 2026, and close on August 24, 2026. The last date for the payment of consideration to shareholders is September 8, 2026. Public shareholders holding shares in both dematerialized and physical forms are eligible to participate in the offer through the BSE acquisition window.